On Nov. 19, the U.S. Food and Drug Administration (FDA) allowed marketing of four diagnostic devices that can be used for high throughput gene sequencing, often referred to as “next generation sequencing” (NGS). Read more.
FDA allows marketing of ‘next generation’ gene sequencing devices
Authosr(s):
